drugset / Trial / NCT02039362

Prevention of Hepatitis B Virus Vertical Transmission by Serovaccination and Tenofovir During Pregnancy

NCT02039362

Phase 4 Completed 37 enrolled Hopital Lariboisière
NaSingle-groupOpen-labelPrevention

Summary

The risk of vertical HBV transmission is related to HBV DNA level in pregnant women, around 30% in women with HBV DNA above 1, 000 000 I.U/mL despite serovaccination of newborns. Using tenofovir DF during the last trimester of pregnancy allows to reduce the risk, but data from Western countries are needed.

Timeline

Start
2012-07
Primary completion
2016-01
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir disoproxil fumarate Small molecule 245 mg